Nurtec\rimegepant\瑞美吉泮 rimegepant

Drug Class

Calcitonin gene-related peptide (CGRP) receptor antagonist

Mechanism

Rimegepant is a small-molecule calcitonin gene-related peptide (CGRP) receptor antagonist that competes with CGRP for receptor binding, inhibiting CGRP-induced vasodilation and neurogenic inflammation.

Approved Indication

Acute treatment of migraine with or without aura, and preventive treatment of episodic migraine in adults.

What This Means For Patients

Nurtec\rimegepant\瑞美吉泮 is not distributed through mainland China's retail pharmacy network. Uwell Cloud can help arrange a purchase channel for this medicine, sourced and dispatched from Hong Kong; clinical administration support in China can be coordinated on request. Availability and eligibility for any specific patient are determined by clinical review.

Regulatory Approvals

• FDA — Approved (2020) — Sources
• EMA — Approved (2022) — Sources
• NMPA — Approved (2024) — Sources

Pivotal Clinical Evidence

• NCT03461757 — Croop et al., Lancet 2019 (NCT03461757) — Sources

Sources

• https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212725s000lbl.pdf
• https://www.ema.europa.eu/en/medicines/human/EPAR/vydura
• https://www.nmpa.gov.cn/